Print  |  Close

A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)


Active: Yes
Cancer Type: Bone and Soft Tissue (including Sarcoma) NCT ID: NCT03327857
Trial Phases: Phase I Protocol IDs: 2017.002.01 (primary)
NCI-2018-01343
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: AbGenomics International, Inc.
NCI Full Details: http://clinicaltrials.gov/show/NCT03327857

Summary

To establish the pharmacokinetic, pharmacodynamic, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory acute graft-versus-host disease(sr-aGvHD)

Objectives

This study is a Phase I, single dose, dose-escalation study to study the pharmacokinetics, safety, signs of efficacy, receptor occupancy and pharmacodynamics biomarkers (REG3-alpha and ST2 of Neihulizumab in patients with steroid-refractory acute GvHD. Up to 24 patients will be recruited in 4-9 clinical centers in US.